Join our daily newsletter At The Bell to receive exclusive market insights
- Little Green Pharma (LGP) will start selling its Desert Flame high THC medicinal cannabis flower product in Poland
- Company distribution partner Medezin will hold the marketing authorisation and sell LGP product on a white-label basis
- The company can sell cannabis products with a THC concentration of up to 22 per cent
- LGP notes retail prices can run as high as A$25 per gram
- Shares last traded at 18.5 cents
Little Green Pharma (LGP) has been granted marketing authorisation for its Desert Flame high THC medicinal cannabis flower product in Poland.
Under Polish law, marketing authorisation is the only legal way to provide medicinal cannabis in the jurisdiction. The company expects a 16 per cent compound annual growth rate within the medicinal cannabis market in Poland.
In Poland, there are currently ten marketing authorisations for cannabis flower products with a THC content in the range of 18 to 22 per cent.
Company distribution partner Medezin will hold the marketing authorisation and sell the product on a white-label basis, using Medezin’s branding.
Medezin is itself a subsidiary of Pelion Group SA, Poland and Lithuania’s largest healthcare operator. Little Green Pharma expects the first shipment to be sent off in October.
Wholesale cannabis flower prices fetch up to A$15.00 per gram, while retail prices are higher at up to A$25 per gram.
Little Green Pharma shares last traded at 18.5 cents.
